Effect of resveratrol on blood pressure: A meta-analysis of randomized controlled trials

Clinical Nutrition

Volumn 34, Issue 1, 2015, Pages 27-34

  Liu, Yanxia ^a   Ma, Wanqiang ^b   Zhang, Po ^a   He, Shunchuan ^a   Huang, Daifa ^a  

^a GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

^b The 210th Hospital of PLA   (China)

Author keywords

BMI; CVD; DBP; Diastolic blood pressure; GE; GE RES; Meta analysis; RCTs; Resveratrol; SBP; Systolic blood pressure; T2DM

Indexed keywords

RESVERATROL; STILBENE DERIVATIVE;

ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; BODY MASS; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; HUMAN; LOW DRUG DOSE; META ANALYSIS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; DIASTOLE; DRUG EFFECTS; MEDLINE; REGRESSION ANALYSIS; SYSTOLE;

BLOOD PRESSURE; DIASTOLE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MEDLINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS; STILBENES; SYSTOLE;

EID: 84921439560     PISSN: 02615614     EISSN: 15321983     Source Type: Journal    
DOI: 10.1016/j.clnu.2014.03.009     Document Type: Article

References (43)

1. Worlld Health Organization Cardiovascular disease: global atlas on cardiovascular disease prevention and control 2012, WHO, Geneva, Switzerland.
2. Smith S.C., Collins A., Ferrari R., Holmes D.R., Logstrup S., McGhie D.V., et al. Our time: a call to save preventable death from cardiovascular disease (heart disease and stroke). JAm Coll Cardiol 2012, 60:2343-2348.
3. Tome-Carneiro J., Gonzalvez M., Larrosa M., Yanez-Gascon M.J., Garcia-Almagro F.J., Ruiz-Ros J.A., et al. Resveratrol in primary and secondary prevention of cardiovascular disease: a dietary and clinical perspective. Ann N Y Acad Sci 2013, 1290:37-51.
4. Das M., Das D.K. Resveratrol and cardiovascular health. Mol Aspects Med 2010, 31:503-512.
5. Wang H., Yang Y.J., Qian H.Y., Zhang Q., Xu H., Li J.J. Resveratrol in cardiovascular disease: what is known from current research. Heart Fail Rev 2012, 17:437-448.
6. Dohadwala M.M., Vita J.A. Grapes and cardiovascular disease. JNutr 2009, 139:1788S-1793S.
7. Adab P., Cheng K.K., Jiang C.Q., Zhang W.S., Lam T.H. Age-specific relevance of usual blood pressure to vascular mortality. Lancet 2003, 361:1391. author reply 1391-2.
8. Collins R., MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull 1994, 50:272-298.
9. Lewington S., Clarke R., Qizilbash N., Peto R., Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360:1903-1913.
10. Barona J., Aristizabal J.C., Blesso C.N., Volek J.S., Fernandez M.L. Grape polyphenols reduce blood pressure and increase flow-mediated vasodilation in men with metabolic syndrome. JNutr 2012, 142:1626-1632.
11. Feringa H.H., Laskey D.A., Dickson J.E., Coleman C.I. The effect of grape seed extract on cardiovascular risk markers: a meta-analysis of randomized controlled trials. JAm Diet Assoc 2011, 111:1173-1181.
12. van Mierlo L.A., Zock P.L., van der Knaap H.C., Draijer R. Grape polyphenols do not affect vascular function in healthy men. JNutr 2010, 140:1769-1773.
13. Sivaprakasapillai B., Edirisinghe I., Randolph J., Steinberg F., Kappagoda T. Effect of grape seed extract on blood pressure in subjects with the metabolic syndrome. Metabolism 2009, 58:1743-1746.
14. Sano A., Uchida R., Saito M., Shioya N., Komori Y., Tho Y., et al. Beneficial effects of grape seed extract on malondialdehyde-modified LDL. JNutr Sci Vitaminol (Tokyo) 2007, 53:174-182.
15. Ward N.C., Hodgson J.M., Croft K.D., Burke V., Beilin L.J., Puddey I.B. The combination of vitamin C and grape-seed polyphenols increases blood pressure: a randomized, double-blind, placebo-controlled trial. JHypertens 2005, 23:427-434.
16. Clifton P.M. Effect of grape seed extract and quercetin on cardiovascular and endothelial parameters in high-risk subjects. JBiomed Biotechnol 2004, 2004:272-278.
17. Zou J.G., Wang Z.R., Huang Y.Z., Cao K.J., Wu J.M. Effect of red wine and wine polyphenol resveratrol on endothelial function in hypercholesterolemic rabbits. Int J Mol Med 2003, 11:317-320.
18. Lekli I., Szabo G., Juhasz B., Das S., Das M., Varga E., et al. Protective mechanisms of resveratrol against ischemia-reperfusion-induced damage in hearts obtained from Zucker obese rats: the role of GLUT-4 and endothelin. Am J Physiol Heart Circ Physiol 2008, 294:H859-H866.
19. Liu Z., Song Y., Zhang X., Liu Z., Zhang W., Mao W., et al. Effects of trans-resveratrol on hypertension-induced cardiac hypertrophy using the partially nephrectomized rat model. Clin Exp Pharmacol Physiol 2005, 32:1049-1054.
20. Moher D., Pham B., Jones A., Cook D.J., Jadad A.R., Moher M., et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses. Lancet 1998, 352:609-613.
21. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
22. Follmann D., Elliott P., Suh I., Cutler J. Variance imputation for overviews of clinical trials with continuous response. JClin Epidemiol 1992, 45:769-773.
23. Movahed A., Nabipour I., Lieben L.X., Thandapilly S.J., Yu L., Kalantarhormozi M., et al. Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients. Evid Based Complement Altern Med 2013, 2013:851267.
24. Bhatt J.K., Thomas S., Nanjan M.J. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr Res 2012, 32:537-541.
25. Yoshino J., Conte C., Fontana L., Mittendorfer B., Imai S., Schechtman K.B., et al. Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metab 2012, 16:658-664.
26. Tome-Carneiro J., Gonzalvez M., Larrosa M., Yanez-Gascon M.J., Garcia-Almagro F.J., Ruiz-Ros J.A., et al. One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease. Am J Cardiol 2012, 110:356-363.
27. Fujitaka K., Otani H., Jo F., Jo H., Nomura E., Iwasaki M., et al. Modified resveratrol Longevinex improves endothelial function in adults with metabolic syndrome receiving standard treatment. Nutr Res 2011, 31:842-847.
28. Timmers S., Konings E., Bilet L., Houtkooper R.H., van de Weijer T., Goossens G.H., et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 2011, 14:612-622.
29. Ishii M. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, and 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. Nihon Rinsho 2000, 58(Suppl.1):267-275.
30. Boocock D.J., Patel K.R., Faust G.E., Normolle D.P., Marczylo T.H., Crowell J.A., et al. Quantitation of trans-resveratrol and detection of its metabolites in human plasma and urine by high performance liquid chromatography. JChromatogr B Analyt Technol Biomed Life Sci 2007, 848:182-187.
31. Walle T., Hsieh F., DeLegge M.H., Oatis J.E., Walle U.K. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 2004, 32:1377-1382.
32. Rivera L., Moron R., Zarzuelo A., Galisteo M. Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem Pharmacol 2009, 77:1053-1063.
33. Inanaga K., Ichiki T., Matsuura H., Miyazaki R., Hashimoto T., Takeda K., et al. Resveratrol attenuates angiotensin II-induced interleukin-6 expression and perivascular fibrosis. Hypertens Res 2009, 32:466-471.
34. Chan V., Fenning A., Iyer A., Hoey A., Brown L. Resveratrol improves cardiovascular function in DOCA-salt hypertensive rats. Curr Pharm Biotechnol 2011, 12:429-436.
35. Toklu H.Z., Sehirli O., Ersahin M., Suleymanoglu S., Yiginer O., Emekli-Alturfan E., et al. Resveratrol improves cardiovascular function and reduces oxidative organ damage in the renal, cardiovascular and cerebral tissues of two-kidney, one-clip hypertensive rats. JPharm Pharmacol 2010, 62:1784-1793.
36. Miatello R., Vazquez M., Renna N., Cruzado M., Zumino A.P., Risler N. Chronic administration of resveratrol prevents biochemical cardiovascular changes in fructose-fed rats. Am J Hypertens 2005, 18:864-870.
37. Robich M.P., Chu L.M., Chaudray M., Nezafat R., Han Y., Clements R.T., et al. Anti-angiogenic effect of high-dose resveratrol in a swine model of metabolic syndrome. Surgery 2010, 148:453-462.
38. Csiszar A., Labinskyy N., Olson S., Pinto J.T., Gupte S., Wu J.M., et al. Resveratrol prevents monocrotaline-induced pulmonary hypertension in rats. Hypertension 2009, 54:668-675.
39. Rush J.W., Quadrilatero J., Levy A.S., Ford R.J. Chronic resveratrol enhances endothelium-dependent relaxation but does not alter eNOS levels in aorta of spontaneously hypertensive rats. Exp Biol Med (Maywood) 2007, 232:814-822.
40. Thandapilly S.J., Wojciechowski P., Behbahani J., Louis X.L., Yu L., Juric D., et al. Resveratrol prevents the development of pathological cardiac hypertrophy and contractile dysfunction in the SHR without lowering blood pressure. Am J Hypertens 2010, 23:192-196.
41. Dolinsky V.W., Chan A.Y., Robillard F.I., Light P.E., Des Rosiers C., Dyck J.R. Resveratrol prevents the prohypertrophic effects of oxidative stress on LKB1. Circulation 2009, 119:1643-1652.
42. Mizutani K., Ikeda K., Kawai Y., Yamori Y. Protective effect of resveratrol on oxidative damage in male and female stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 2001, 28:55-59.
43. Vidt D.G., Borazanian R.A. Treat high blood pressure sooner: tougher, simpler JNC 7 guidelines. Cleve Clin J Med 2003, 70:721-728.